新京报贝壳财经讯 振东制药8月24日晚间披露2025年半年报，上半年实现营业收入14.57亿元，同比下降 3.3%；归母净利润793.13万元，同比下降74.13%；基本每股收益0.0077元。 ...

人民财讯8月24日电，振东制药（300158）8月24日晚间披露2025年半年报，上半年实现营业收入14.57 亿元，同比下降3.3%；归母净利润793.13万元，同比下降74.13%；基本每股收益0.0077元。 ...

Core Viewpoint - Shanxi Zhendong Pharmaceutical Co., Ltd. has announced the use of its own funds for cash management, with a maximum investment of RMB 1 billion, aimed at improving fund utilization efficiency while ensuring normal operations and liquidity [1][2]. Group 1: Cash Management Details - The purpose of the investment is to enhance fund utilization efficiency without affecting normal operations and ensuring fund safety [2]. - The company plans to invest in low to medium-risk financial products issued by banks, securities firms, trust companies, and asset management companies, excluding high-risk investment types [2]. - The resolution is valid for one year from the date of approval by the board [2]. - The management is authorized to implement the cash management within the specified limit [2]. Group 2: Risk Management Measures - The company will adhere to prudent investment principles, selecting low to medium-risk investment products, with the finance department monitoring progress and addressing risks promptly [3]. - The supervisory department will audit and supervise the use and custody of funds for investment products, estimating potential returns and losses [3]. - The supervisory board has the authority to oversee the use of funds and may hire professional institutions for auditing if necessary [3]. Group 3: Board and Supervisory Approval - The proposal received approval from both the board and the supervisory board, which deemed it beneficial for improving fund utilization efficiency and cash management returns, aligning with the interests of the company and all shareholders [3].

Core Insights - The company reported a total operating revenue of 1.457 billion yuan for the first half of 2025, representing a year-on-year decrease of 3.30% [1] - The net profit attributable to shareholders of the listed company was 7.9313 million yuan, showing a significant decline of 74.13% compared to the previous year [1] - The company recorded a net loss of 8.1764 million yuan after deducting non-recurring gains and losses [1] - Basic earnings per share were reported at 0.0077 yuan [1]

Group 1 - The company reported a revenue of 1.457 billion yuan for the first half of 2025, representing a year-on-year decrease of 3.30% [1] - The net profit attributable to shareholders of the listed company was 7.9313 million yuan, down 74.13% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -8.1764 million yuan [1] - The basic earnings per share were 0.0077 yuan [1]

Group 1 - The company, Zhendong Pharmaceutical, announced on August 24 that its sixth board meeting was held on August 22, 2025, where it reviewed the proposal for cash management using its own funds [1] - For the year 2024, Zhendong Pharmaceutical's revenue composition is as follows: 77.86% from pharmaceutical production and sales, 21.34% from medicinal herb planting, and 0.79% from other businesses [1] - As of the report date, Zhendong Pharmaceutical has a market capitalization of 8.4 billion yuan [1]

证券代码：300158 证券简称：振东制药 公告编号：2025-047 山西振东制药股份有限公司 关于股东股份解押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"本公司"）于 近日接到控股股东山西振东健康产业集团有限公司（以下简称"振 东集团"）通知，获悉其所持有的本公司部分股份解除质押，具体 事项如下： 一、股东股份解押基本情况 | 股东名称 | 是否为控 | 本次解押数量 | 占其所 持股份 | 占公司 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 股股东 | （股） | 比例 | 总股本 比例 | | | | | 振东集团 | 是 | 6,300,000 | 2.08% | 0.63% | 2024.09.26 | 2025.08.21 | 中国农业银行股份有限 公司长治上党支行 | | 振东集团 | 是 | 3,350,000 | 1.11% | 0.33% | 2024.03.11 | 2025 ...

山西振东制药股份有限公司 | 资金占用 | | 占用方与上市公 | 上市公司核算的 | 年期初 2025 | 年 月 2025 1-6 | 年 2025 1-6 | 年 月 2025 6 | 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 方类别 | 资金占用方名称 | 司的关联关系 | 会计科目 | 占用资金余 | 占用累计发生 | 月偿还累计 | 30日占用资 | 因 | 占用性质 | | | | | | 额 | 金额 | 发生额 | 金余额 | | | | 控股股东、 | | | | | | | | | | | 实际控制 | | | | | | | | | | | 人及其附 | | | | | | | | | | | 属企业 | | | | | | | | | | | 小计 | —— | —— | —— | | | | | —— | —— | | | 山西振东安装装饰工程有限公司 | 同一实际控制 | 其他会计科目 | 224.43 | 11.51 | 27.30 | 208.64 | 工程款 | 经营性 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-046 山西振东制药股份有限公司 关于公司及其子公司使用自有资金进行现金管理的公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"或"振东制药"）于 2025 年 8 月 22 日召开了第六届董事会第四次会议及第六届监事会第 四次会议，审议通过了《关于公司及其子公司使用自有资金进行现金 管理的议案》。同意在确保不影响公司正常经营以及保证流动性和资 金安全的前提下，公司使用自有资金不超过人民币 10 亿元进行现金 管理，并授权管理层在上述额度内负责办理实施，授权期限自公司第 六届董事会第四次会议审议通过之日起一年。相关情况公告如下： 一、使用自有资金进行现金管理的基本情况 （一）投资目的 为了进一步提高资金使用效率，在确保不影响公司正常经营以及 保证流动性和资金安全的前提下，公司及其子公司使用自有资金进行 现金管理。 （二）投资品种 公司在保证资金安全的前提下充分利用自有闲置资金，合理布局 资产，创造更多收益，拟使用闲置自有资金购买投资品种包括商业银 行、 ...

证券代码：300158 证券简称：振东制药 公告编号：2025-041 2025 年 8 月 25 日 山西振东制药股份有限公司2025年半年度报告及摘要于2025年 8 月 25 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，请投资者注意查阅。 特此公告。 山西振东制药股份有限公司董事会 山西振东制药股份有限公司 2025 年半年度报告披露提示性公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， | | --- | | 没有虚假记载、误导性陈述或重大遗漏。 | ...